PharVision Advisers’s Axcelis ACLS Stock Holding History

PharVision Advisers’s Portfolio ACLS Stock Details ACLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,922	Closed	-$204K	–	265
2024 Q4	$204K	Buy	+2,922	New	+$243K	0.17%	293

Other funds holding ACLS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Reinhart Partners Mequon, Wisconsin $4.38B AUM 55.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

PharVision Advisers's ACLS Position: Q1 2025 in Review

PharVision Advisers sold out of Axcelis (ACLS) in Q1 2025, closing a stake of 2,922 shares — an estimated $204K sold.

PharVision Advisers first reported a position in ACLS in Q4 2024 and held it in 1 quarter. The position peaked at $204K in Q4 2024. 305 funds tracked by Wall St. Rank hold ACLS as of Q1 2025.

PharVision Advisers reported no remaining Axcelis position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 2,922 Axcelis shares in Q1 2025, an estimated $204K.
PharVision Advisers first reported a position in Axcelis in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Axcelis position peaked at $204K in Q4 2024.
305 funds tracked by Wall St. Rank held Axcelis as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.